BRPI0717035B8 - moduladores de benzotriazol cinase - Google Patents

moduladores de benzotriazol cinase

Info

Publication number
BRPI0717035B8
BRPI0717035B8 BRPI0717035A BRPI0717035A BRPI0717035B8 BR PI0717035 B8 BRPI0717035 B8 BR PI0717035B8 BR PI0717035 A BRPI0717035 A BR PI0717035A BR PI0717035 A BRPI0717035 A BR PI0717035A BR PI0717035 B8 BRPI0717035 B8 BR PI0717035B8
Authority
BR
Brazil
Prior art keywords
benzotriazole
kinase modulators
modulators
kinase
jnk
Prior art date
Application number
BRPI0717035A
Other languages
English (en)
Inventor
Sidduri Achyutharao
Michoud Christophe
Michael Goldstein David
Gong Leyi
Solang Palmer Wylie
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0717035A2 publication Critical patent/BRPI0717035A2/pt
Publication of BRPI0717035B1 publication Critical patent/BRPI0717035B1/pt
Publication of BRPI0717035B8 publication Critical patent/BRPI0717035B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

moduladores de benzotriazol cinase. a presente invenção refere-se a novos derivados de benzotriazol de fórmula (i) em que r1, r2, r3, e m são como definidos na descrição e nas reivindicações, bem como sais fisiologicamente aceitáveis destes. estes compostos são moduladores de jnk e cdk.
BRPI0717035A 2006-09-08 2007-08-30 moduladores de benzotriazol cinase BRPI0717035B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84309006P 2006-09-08 2006-09-08
US60/843,090 2006-09-08
PCT/EP2007/059040 WO2008028860A1 (en) 2006-09-08 2007-08-30 Benzotriazole kinase modulators

Publications (3)

Publication Number Publication Date
BRPI0717035A2 BRPI0717035A2 (pt) 2014-11-25
BRPI0717035B1 BRPI0717035B1 (pt) 2021-05-04
BRPI0717035B8 true BRPI0717035B8 (pt) 2021-05-25

Family

ID=38893293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717035A BRPI0717035B8 (pt) 2006-09-08 2007-08-30 moduladores de benzotriazol cinase

Country Status (17)

Country Link
US (1) US8962622B2 (pt)
EP (1) EP2066319B1 (pt)
JP (1) JP5325783B2 (pt)
KR (1) KR101177729B1 (pt)
CN (1) CN101511359B (pt)
AR (1) AR062666A1 (pt)
AT (1) ATE543498T1 (pt)
AU (1) AU2007293917B2 (pt)
BR (1) BRPI0717035B8 (pt)
CA (1) CA2662998C (pt)
CL (1) CL2007002572A1 (pt)
ES (1) ES2378577T3 (pt)
IL (1) IL197015A (pt)
MX (1) MX2009002229A (pt)
PE (1) PE20080659A1 (pt)
TW (1) TW200819440A (pt)
WO (1) WO2008028860A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
RU2493155C2 (ru) 2006-12-08 2013-09-20 Ф.Хоффманн-Ля Рош Аг Замещенные пиримидины и их применение в качестве модуляторов jnk
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
ES2392788T3 (es) * 2008-05-16 2012-12-13 F. Hoffmann-La Roche Ag Inhibidores de las JNK
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CA2749236A1 (en) 2009-02-24 2010-09-02 F. Hoffmann-La Roche Ag Imidazo [1,2-a] pyridines as jnk modulators
CN102471319B (zh) * 2009-08-10 2014-06-18 霍夫曼-拉罗奇有限公司 Jnk的抑制剂
BR112012030814A2 (pt) * 2010-06-04 2019-09-24 Hoffmann La Roche inibidores de jnk
EP2576537B1 (en) * 2010-06-04 2016-03-16 F.Hoffmann-La Roche Ag 2-amino-pyrimidine derivatives useful as inhibitors of jnk
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
KR101860971B1 (ko) * 2011-02-09 2018-07-05 더루우브리졸코오포레이션 아스팔텐 분산제 함유 윤활 조성물
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
HUE042032T2 (hu) 2013-02-25 2019-06-28 Aurigene Discovery Tech Ltd Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206563A2 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
RU2016141934A (ru) 2014-04-04 2018-05-07 Сирос Фармасьютикалз, Инк. Ингибиторы циклин-зависимой киназы 7 (cdk7)
CN106661050A (zh) * 2014-06-16 2017-05-10 阿林齐生物制药公司 用于治疗和预防神经系统的退行性疾病的p38和JNK MAPK抑制剂
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
CN108117523B (zh) * 2016-11-29 2021-05-07 上海医药工业研究院 卤代尿嘧啶类化合物的制备方法
IL270066B2 (en) 2017-04-24 2023-10-01 Aurigene Oncology Ltd Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
KR102861339B1 (ko) 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
CN120737038A (zh) * 2020-09-15 2025-10-03 田边三菱制药株式会社 三嗪化合物的制造方法
CN114456126A (zh) * 2022-02-26 2022-05-10 郑州萃智医药科技有限公司 一种化合物的合成方法
CN115677595B (zh) * 2022-10-26 2024-06-14 江苏睿实生物科技有限公司 一种2,4,5-三氯嘧啶的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
EP1554269A1 (en) 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
ES2396135T3 (es) 2004-06-10 2013-02-19 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
WO2007111904A2 (en) 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders

Also Published As

Publication number Publication date
KR20090040908A (ko) 2009-04-27
PE20080659A1 (es) 2008-05-17
CA2662998C (en) 2015-10-06
AU2007293917B2 (en) 2013-01-31
EP2066319B1 (en) 2012-02-01
CA2662998A1 (en) 2008-03-13
CN101511359B (zh) 2012-09-05
US20080103142A1 (en) 2008-05-01
US8962622B2 (en) 2015-02-24
ATE543498T1 (de) 2012-02-15
IL197015A (en) 2013-12-31
WO2008028860A1 (en) 2008-03-13
JP5325783B2 (ja) 2013-10-23
CN101511359A (zh) 2009-08-19
KR101177729B1 (ko) 2012-09-07
MX2009002229A (es) 2009-03-16
BRPI0717035A2 (pt) 2014-11-25
ES2378577T3 (es) 2012-04-16
TW200819440A (en) 2008-05-01
BRPI0717035B1 (pt) 2021-05-04
AR062666A1 (es) 2008-11-26
EP2066319A1 (en) 2009-06-10
CL2007002572A1 (es) 2008-04-18
IL197015A0 (en) 2009-11-18
AU2007293917A1 (en) 2008-03-13
JP2010502668A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
ECSP088549A (es) Nuevos derivados de pirrol fusionado
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
BR112012006531A2 (pt) derivados de imidazopirimidina ou imidazopiridina como inibidores da fosfodiesterase 10a.
BR112012031343A2 (pt) compostos de heteroarila contendo nitrogênio
BRPI0511621A (pt) compostos orgánicos
BR112012010186A2 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3.
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
BR112012017580A2 (pt) derivados de heteroarila contendo nitrogênio
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
CR9602A (es) Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
CR11176A (es) Formulaciones liquidas solubles de sales amonicas de quinclorac
MX2009003383A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BR112014004522A2 (pt) moduladores de pde10
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
NI201000188A (es) Derivados de piperidina 3,4-sustituida como inhibidores de renina.
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
BR112012011064A2 (pt) novos compostos de diazinilpirazolila.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF